Who Paid My Doc
Adam Landsman
Podiatrist, Foot Surgery Boston, MA Doctor of Podiatric Medicine
NPI 1407854094 CMS profile 18887
55 Fruit Street, Dept. Of Orthopaedics/Podiatry Service, Boston, MA 02114
General payments
$384,938
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Adam Landsman of Boston, MA is reported in the CMS Open Payments database as having received $384,938 across 304 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 99th percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $41,553 | 21 | |
| 2024 | General | $35,526 | 21 | |
| 2023 | General | $39,322 | 43 | |
| 2022 | General | $59,341 | 83 | |
| 2021 | General | $75,473 | 45 | |
| 2020 | General | $64,908 | 32 | |
| 2019 | General | $68,817 | 59 |
Beside peers
- Adam Landsman
- Podiatrist, Foot Surgery median
- Middle half of Podiatrist, Foot Surgery
- National median
In program year 2025, general payments to Adam Landsman were reported at $41,553. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.
Show as a table
| Year | Adam Landsman | Podiatrist, Foot Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $68,817 | $167 | $67–$484 | $163 |
| 2020 | $64,908 | $114 | $40–$323 | $114 |
| 2021 | $75,473 | $171 | $57–$502 | $132 |
| 2022 | $59,341 | $196 | $66–$556 | $149 |
| 2023 | $39,322 | $187 | $78–$466 | $160 |
| 2024 | $35,526 | $190 | $78–$557 | $164 |
| 2025 | $41,553 | $180 | $70–$569 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 16 drugsPart D claims
466
Drug cost
$55,788
Branded share of claims
17.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jublia Efinaconazole | Brand | 32 | $48,668 | |
| Lidocaine | Generic | 30 | $2,997 | |
| Diclofenac Sodium | Generic | 46 | $1,095 | |
| Ammonium Lactate | Generic | 44 | $642 | |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | Brand | 17 | $396 | |
| Pregabalin | Generic | 22 | $329 | |
| Terbinafine Hcl | Generic | 38 | $323 | |
| Doxycycline Monohydrate | Generic | 36 | $266 | |
| Econazole Nitrate | Generic | 11 | $265 | |
| Meloxicam | Generic | 92 | $223 |
The 10 drugs with the highest cost, of 16 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 67 billing codesPaid by Medicare
$153,598
Medicare patients
559
Services billed
3,123
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 72% | |
| Arthritis | 56% | |
| Diabetes | 38% | |
| Ischemic heart disease | 32% | |
| Chronic kidney disease | 30% | |
| Depression | 26% | |
| Atrial fibrillation | 23% | |
| Osteoporosis | 23% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 18 | 31 | $21 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 18 | 244 | $19 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
304 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist, Foot Surgery in Massachusetts
Mark Rose
Podiatrist, Foot Surgery · Natick, MA
Jamey Allen
Podiatrist, Foot Surgery · Woburn, MA
Ewald Mendeszoon
Podiatrist, Foot Surgery · West Roxbury, MA
Christopher Locke
Podiatrist, Foot Surgery · Boston, MA
Jurgen Fernandez
Podiatrist, Foot Surgery · Lynn, MA
Justin Ogbonna
Podiatrist, Foot Surgery · Boston, MA
Related records
Podiatrist, Foot Surgery in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist, Foot Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.